Net (Loss) Income per Common Share

9 Months Ended

Dec. 31, 2025

Basic net (loss) income per common share is computed by dividing net (loss) income attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net (loss) income attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period.

For periods of loss from continuing operations, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. For the three and nine months ended December 31, 2025 and 2024, all outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss from continuing operations.

As of December 31, 2025 and 2024, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net (loss) income per common share:


	December 31, 2025	December 31, 2024
Stock options and performance stock options	97,405,163	141,783,273
Restricted stock units and performance stock units (non-vested)	63,658,800	51,484,611
March 2020 CVARs(1)	17,548,368	17,548,368
November 2021 CVARs (non-vested)	—	710,060
Restricted common stock (non-vested)	—	169,422
Earn-Out Shares (non-vested)	—	3,080,387
Other stock based awards and instruments issued	3,674,484	5,031,399

(1)Refer to Note 9, “Share-Based Compensation and Other Compensation Plans” for details regarding settlement of CVARs.

Roivant Sciences Ltd. 10-Q